Company intelligence / Profile preview
Couragene
North Brunswick, New Jersey, United Statescouragene.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Couragene is developing in vivo genetic therapies using the STEP platform for delivery of gene editors, supported by a $40M NIH SCGE grant for Angelman syndrome and H1-4 syndrome. No clinical results reported yet.
- Therapeutic areas
- NeurologyRare Diseases
- Modalities
- Gene therapyGene editingNon-viral delivery
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Couragene.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Couragene.